OL Oncology Letters 1792-1074 1792-1082 D.A. Spandidos 10.3892/ol.2022.13214 OL-23-03-13214 Articles Minecoside promotes apoptotic progression through STAT3 inactivation in breast cancer cells KimBuyun 1 2 LeeKi Yong 3 ParkByoungduck 1 College of Pharmacy, Keimyung University, Dalseo-Gu, Daegu, North Gyeongsang 704-701, Republic of Korea Korean Medicine Application Center, Korea Institute of Oriental Medicine, Daegu, North Gyeongsang 701-300, Republic of Korea College of Pharmacy, Korea University, Sejong 339-770, Republic of Korea Correspondence to: Dr Byoungduck Park, College of Pharmacy, Keimyung University, 1095 Dalgubeoldaero, Dalseo-Gu, Daegu, North Gyeongsang 704-701, Republic of Korea, E-mail: bdpark@kmu.ac.kr Dr Ki Yong Lee, College of Pharmacy, Korea University, Sejong Campus 2511 Sejong-ro, Sejong 339-770, Republic of Korea, E-mail: kylee11@korea.ac.kr 03 2022 27 01 2022 23 3 94 24082021 04012022 Copyright: © Kim et al. 2022 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Breast cancer is one of the most common malignant tumors in women worldwide, and is a major cause of mortality and morbidity in cancer patients. Constitutive activation of STAT3 has been found in a variety of malignant tumors, including breast cancer. Since STAT3 activation is capable of regulating various important features of tumor cells, identification of a novel STAT3 inhibitor is considered a potential strategy for treating breast cancer. The aim of the present study was to examine whether minecoside (MIN), an active compound extracted from Veronica peregrina L., exerts an antitumor effect by inhibiting STAT3 signaling pathway in MDA-MB-231 cells. The results revealed that MIN inhibited the constitutive STAT3 activation in a dose- and time-dependent manner. MIN also blocked the nuclear translocation of STAT3 and suppressed STAT3-DNA binding. In addition, MIN downregulated the STAT3-mediated expression of proteins such as Bcl-xL, Bcl-2, CXCR4, VEGF, and cyclin D1. Subsequently, MIN promoted the caspase-dependent apoptosis in MDA-MB-231 cells. Overall, results of the present study provide evidence that MIN exerted anticancer activity via inhibition of the STAT3 signaling pathway. Further studies using animal models are required to determine the potential of this molecule as an anticancer drug.

 breast cancer minecoside STAT3 inactivation Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) Ministry of Health & Welfare, Republic of Korea HF20C0038 This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HF20C0038). Introduction

Breast cancer is one of the most common malignant tumors in women worldwide, and triple-negative breast cancer accounts for 15-20% of all breast cancer cases (1,2). At present, various clinical trials have been conducted to treat and delay the progression of breast cancer, but mortality and morbidity among patients remain high (3). Several carcinogens and signaling pathways are known to be involved in the progression of breast cancer. Among them, signal transducer and activator of transcription 3 (STAT3) has been reported to play a pivotal role in breast cancer development (4). Unlike normal cells, in which the activity of STAT3 is strictly regulated, STAT3 activity in breast cancer contributes to tumorigenesis in a multifaceted manner (5). Interleukin-6 (IL-6), G-protein-coupled receptors (GPCRs), and Toll-like receptors (TLRs) are known to be involved in STAT3 activation in various types of cancer, including colon cancer (6,7). Once STAT3 signaling is activated, it induces carcinogenesis through the expression of various genes associated with apoptosis (survivin, Bcl-xL, and Bcl-2), proliferation (cyclin D1), and angiogenesis (VEGF) (8,9). Additionally, several protein tyrosine phosphatases (PTPs) promote the death of cancer cells by STAT3 inactivation (10,11). SH2 domain containing phosphatase 1/2 (SHP-1/2) and protein tyrosine phosphatase 1B (PTP-1B) are known to be associated with STAT3 inactivation. SHP-1 is highly expressed in normal lymphocytes, whereas its expression is decreased in most cancer cells (12). In addition, SHP-1 expression in cancer cells effectively suppresses target genes such as VEGF-1, cyclin D1, and survivin (13). Thus, dephosphorylation of STAT3 by increasing the expression of SHP-1 may be an efficient strategy for the treatment of various cancer types.

In previous decades, many researchers have suggested that natural compounds may act as potent anti-cancer drugs with high efficacy and low side effects. Various candidates have been studied and examined for their anti-cancer properties and underlying mechanisms. Minecoside (MIN), an active compound extracted from Veronica peregrina L., belongs to the family Scrophulariaceae (14). The entire plant has been used as a traditional drug for the treatment of menstrual irregularities, fractures, and traumatic injuries (14). Moreover, several compounds from Veronica peregrina L. have been reported to exhibit antioxidant activity (14). A recent study revealed that MIN suppressed the invasive capability of cancer cells by inhibiting CXCR4 expression via blocking NF-κB (15). However, the mechanism underlying the regulation of STAT3 activation by MIN has not been completely understood. Therefore, we investigated whether MIN could modulate the apoptosis of breast cancer cells by regulating the STAT3 signaling pathway.

 Materials and methods <sec> <title>Purity analysis of minecoside

Minecoside was isolated from the Catalpa ovata according to a previously protocol (16). Purity analysis of isolated minecoside was carried on Shiseido CapCell PAK C18 column (Sigma-Aldrich) particle size 5 µm (150×4.6 mm) using a Waters 2695 system (Waters Corporation). The mobile phase consisted of water with 0.1% formic acid (solvent A), acetonitrile with 0.1% formic acid (solvent B), which were applied in the following gradient elution: 5% B (0–5 min), 5-95% B (5–30 min). The injection volume was 10 µl, and the flow rate was 0.6 ml/min. The UV chromatogram of minecoside was acquired at 330 nm and integrated. Purity of minecoside was 90.4±0.4%. The chemical structure of MIN is shown in Fig. 1A. As preliminary experiments with minecoside (MIN) had been performed by the authors, identical conditions were adhered to throughout the study (15).

 Materials

Antibodies against phospho-STAT3 (1:1,000; rabbit, monoclonal; cat. no. 9145), STAT3 (1:1,000; rabbit, monoclonal; cat. no. 12640), p-JAK1 (1:1,000; rabbit, polyclonal; cat. no. 3331), p-JAK2 (1:1,000; rabbit, monoclonal; cat. no. 8082), p-Src (1:1,000; rabbit, polyclonal; cat. no. 2101), Src (1:1,000; rabbit, polyclonal; cat. no. 2108), SHP-1 (1:1,000; rabbit, monoclonal; cat. no. 3759), cleaved PARP (1:1,000; rabbit, monoclonal; cat. no. 5625), cleaved caspase-9 (1:1,000; rabbit, monoclonal; cat. no. 7237), cleaved caspase-3 (1:1,000; rabbit, polyclonal; cat. no. 9661), Bcl-2 (1:1,000; rabbit, monoclonal; cat. no. 3498), β-actin (1:1,000; rabbit, monoclonal; cat. no. 4970) and anti-rabbit IgG (1:5,000; rabbit, polyclonal; cat. no. 14708) were obtained from Cell Signaling Technology, Inc. CXCR4 antibody (1:10,000; rabbit, polyclonal; cat. no. ab227767) was obtained from Abcam. Antibodies to VEGF (1:1,000; rabbit, polyclonal; cat. no. sc-152), JAK1 (1:1,000; rabbit, polyclonal; cat. no. sc-277), JAK2 (1:1,000; rabbit, polyclonal; cat. no. sc-278), Bcl-xL (1:1,000; mouse, monoclonal; cat. no. sc-8392), Cyclin D1 (1:1,000; rabbit, polyclonal; cat. no. sc-718) and goat anti-mouse IgG (1:5,000; mouse, monoclonal; cat. no. 2355) were purchased from Santa Cruz Biotechnology, Inc. RIPA buffers were purchased from Cell Signaling Technology, Inc. DMEM, fetal bovine serum (FBS), and antibiotic-antimycotic mixture were purchased from Gibco BRL; Thermo Fisher Scientific, Inc. The DIG gel shift kit for EMSA was purchased from Roche Diagnostics.

 Cell culture

MDA-MB-231 cells were obtained from the American Type Culture Collection and cultured in DMEM supplemented with 10% FBS and 1% antibiotics at 37°C in a humidified incubator with 5% CO2. For the western blot assay, MDA-MB-231 cells were treated with the indicated concentrations of MIN (0, 12.5, 25, and 50 µM) for 24 h or at the indicated times (0, 6, 12, and 24 h) at 50 µM concentration.

 Cell viability assay by Cell Counting Kit-8 (CCK-8)

To determine the optimal concentration of MIN capable of inhibiting STAT3 activity, MDA-MB-231 cells (5×104 cells/well) were seeded into 96-well plates. MIN was added at various concentrations (0–100 µM) at 37°C for 24 h. Subsequently, 10 µl CCK-8 solution was added to each well, and the cells were incubated at 37°C for 2 h. The cell viability was determined by measuring the absorbance at 490 nm using a GloMax® Explorer Multimode Microplate Reader (Promega Corporation).

 Western blot assay

As described in a previous study (17), whole-cell extracts were lysed with RIPA buffer and then the extracted proteins were separated by 10% SDS-PAGE and electrotransferred to PVDF membranes. The membranes were immunoblotted with the aforementioned primary and secondary antibodies.

 Electrophoretic mobility shift assay (EMSA)

As previously described (17), binding activity of STAT3 to consensus oligonucleotides was measured with extracting nuclear proteins from MIN-treated MDA-MB-231 cells using non-radioactive EMSA assay (DIG Gel Shift Kit; Roche Diagnostics). Oligonucleotide probes labeled with DIG containing consensus binding sites for STAT3 (5-CTTCATTTCCCGTAAATCCCTAAAGCT −3 and 5-AGCTTTAGGGATTTACGGGAAATG A-3) were used.

 Immunofluorescence assay

As described in a previous study (15), immunofluorescence assay was performed to check STAT3 nuclear translocation. The cells were blocked with 5% BSA for 1 h and then incubated with the anti-STAT3 antibody at room temperature for 1 h. After being washed with PBS, the slides were incubated with the secondary antibody Alexa Flour 488 for 30 min and counterstained for nuclei with Hoechst-33342 at 37°C for 10 min. The fluorescence image was measured under ×200 magnification using a fluorescence microscope (Nikon ECLIPSE Ti-U; Nikon Corporation).

 TUNEL assay

Detection of DNA fragments in situ using terminal deoxyribonucleotidyl transferase-mediated dUTP-digoxigenin nick end labeling (TUNEL) assay kits (Roche Diagnostics) was applied to investigate active cell death. Briefly, cells were treated with 50 µM MIN for 24 h, then washed with PBS. The cells were fixed with freshly prepared 4% paraformaldehyde for 1 h at room temperature and treated with 0.2% Triton X-100 solution for 2 min on ice. Intracellular DNA fragments were then labeled by exposing the cells to TUNEL reaction mixture for 1 h at 37°C in a humidified atmosphere, with protection from light. The cells were washed with PBS twice, then transferred to slides and analyzed under a fluorescence microscope (Nikon ECLIPSE Ti-U; Nikon Corporation).

 Statistical analysis

Experimental data are presented as the mean ± SEM obtained from three independent experiments. Statistical significance was assessed by one-way analysis of variance (ANOVA) followed by Tukey's honest significant difference test or Students' t-test using graph pad prism 6 software package (GraphPad Software Inc.) and ImageJ (imagej.nih.gov/ij). The statistics of the cell viability assay and western blot were determined by triplicate experiments using one-way ANOVA with Tukey's post hoc test. The statistical analysis of STAT3 translocation was determined by Students' t-test. P<0.05 was considered to indicate a statistically significant difference.

 Results <sec> <title>MIN downregulates constitutive activation of STAT3 in MDA-MB-231 cells

Since constitutive activation of STAT3 is found in numerous cancer types, including >40% of primary breast tumors (4), and a recent study has reported anti-cancer effects of MIN in breast cancer (15), whether MIN affects STAT3 activation was examined in the present study. To determine the optimal concentration of MIN, the cell viability at the indicated concentrations of MIN (0, 6.25, 12.5, 25, 50, 80 and 100 µM) were evaluated. Based on the results, 50 µM of MIN was selected as an optimal concentration and used throughout the study (Fig. 1B). As shown in Fig. 1C and D, MIN reduced the phosphorylation of STAT3 in a dose- and time-dependent manner in MDA-MB-231 cells. The reduction ratio of phosphorylated STAT3 to STAT3 was from 15 to 55%.

 MIN downregulates upstream signaling pathway responsible for STAT3 activation

Janus kinases 1/2 (JAK1/2) and Src kinase were reported to contribute to STAT3 activation and are involved in cancer cell growth (18). Thus, whether MIN could inhibit the upstream signaling molecules that activate STAT3 was examined. The results showed that MIN suppressed the constitutive activation of JAK1, JAK2, and Src kinase at 50 µM in MDA-MB-231 cells (Fig. 1E).

 MIN suppresses DNA binding of STAT3 in MDA-MB-231 cells

Based on the fact that the phosphorylation of STAT3 regulates gene transcription through dimerization, nuclear translocation, and DNA binding (19), whether MIN can regulate the DNA binding activity of STAT3 was investigated. After cells were treated with the indicated concentrations of MIN for 24 h or with 50 µM of MIN for different time periods, EMSA was performed to examine the DNA binding activity of STAT3. The results showed that MIN suppressed STAT3-DNA binding in a dose- and time-dependent manner (Fig. 2A and B).

To check whether MIN inhibits STAT3-DNA binding by blocking STAT3 nuclear translocation, an immunofluorescence assay was performed. As shown in Fig. 2C, 50 µM MIN suppressed the translocation of STAT3 into the nucleus as compared to the control groups.

 MIN induces the expression of SHP-1

Previous findings showed that, several PTPs can modulate the STAT3 signaling pathway in various cancer cells (20). Therefore, whether the regulation of STAT3 activity by MIN was due to PTP induction was examined. Several studies reported that loss of SHP-1 in cancer cells improves STAT3 signaling (12,21). In addition, SHP-1 was proposed as a promising drug target in the development of STAT3 inhibitors because it can dephosphorylate JAKs (22) as well as STAT3 (11). Thus, whether MIN modulated SHP-1 expression in MDA-MB-231 cells was examined. As shown in Fig. 3A, MIN treatment increased SHP-1 expression in a concentration-dependent manner.

 MIN inhibits the expression of various genes involved in growth, angiogenesis, invasion, and metastasis

STAT3 activation induces the expression of various genes involved in cancer cell survival and proliferation (9). The anti-apoptotic proteins Bcl-2 (23), Bcl-xL (24), invasive protein CXCR4 (25), angiogenic protein VEGF (26), and cell cycle control protein cyclin D1 (27) are known to be induced upon STAT3 activation. Thus, whether MIN affects the expression of these genes by regulating STAT3 activity was investigated. As shown in Fig. 3B and C, MIN downregulated the expression of Bcl-xL, Bcl-2, cyclin D1, VEGF, and CXCR4 in a dose- and time-dependent manner.

 MIN induces caspase-dependent apoptosis in MDA-MB-231 cells

To further examine the apoptotic progression induced by MIN, major proteins involved in the caspase pathway were examined using western blot analysis. The results showed that MIN upregulated the expression of cleaved forms of caspase-9, caspase-3, and PARP in a dose- and time-dependent manner (Fig. 4A and B). To confirm MIN-induced apoptosis, a TUNEL assay, which is a commonly used method for identifying apoptosis, was performed. The TUNEL analysis revealed that MIN increased the number of apoptotic cells (Fig. 4C). Taken together, these results strongly suggested that MIN induced caspase-dependent apoptosis in MDA-MB-231 cells.

 Discussion

Although the specific role of STAT3 in the onset and progression of breast cancer is not fully defined, the activation of IL-6/JAK2/STAT3 pathways is well known to promote carcinogenesis (4,28). In particular, breast cancer is associated with inflammatory conditions with high levels of growth factors and cytokines (6). For example, inflammatory cytokines, such as IL-6, are known to promote cancer cell growth, invasion, migration, metastasis, angiogenesis, and drug resistance through the JAK/STAT3 pathway (23,26,29). Based on the aforementioned studies, we investigated whether MIN promoted apoptosis by inhibiting constitutive STAT3 activation in breast cancer cells.

The results showed that, MIN suppressed constitutive STAT3 activation in MDA-MB-231 cells. The phosphorylation of STAT3 at Tyr705, an important step in STAT3 activation, was inhibited by MIN in a dose- and time-dependent manner. STAT3 phosphorylation is mediated through the activation of non-receptor protein tyrosine kinases such as JAK1 and JAK2. Src kinase is also known to play an important role in the phosphorylation of STAT3 (30,31). Indeed, although upstream kinases are important in tumorigenesis, STAT3, which is considered a key transcription factor for gene expression involved in malignancy, was the primary focus of the present study. The results demonstrated that MIN inhibited JAK1, JAK2, and Src kinase activation, suggesting that MIN suppresses STAT3 phosphorylation via the inactivation of upstream kinases. Since the phosphorylation of STAT3 regulates gene transcription through dimerization, nuclear translocation, and DNA binding (19), whether MIN can affect STAT3 translocation and DNA binding activity was investigated. The results revealed that MIN suppressed STAT3-DNA binding as well as the nuclear translocation of STAT3.

Several PTPs modulate the STAT3 signaling pathway in various cancer cells (20). In particular, the SH2 domain-containing phosphatase-1 (SHP-1) possesses a tumor-suppressive potential by virtue of negatively regulating STAT3 signaling (12); it is considered an antagonist of tyrosine kinases related to tumor growth and anti-apoptosis (32). SHP-1 expression is known to be reduced or abolished in estrogen receptor-negative breast cancer cell lines. In the present study, whether the inhibitory effect of MIN on STAT3 activation was related to SHP-1 expression was examined. The results showed that, MIN treatment increased SHP-1 expression in a concentration-dependent manner. The increase in SHP-1 expression by MIN was confirmed via the association with the inhibition of constitutive STAT3 activation in subsequent experiments. Besides SHP-1, the involvement of other PTPs in the regulation of STAT3 by MIN should be investigated in future studies.

STAT3 activation is observed in various malignant tumors, including lung, breast, liver, colon, prostate, stomach, pancreas, kidney, and brain cancers (33). This is because STAT3 activation upregulates a variety of cellular signaling required for cell survival (Bcl-xL, Bcl-2, c-myc, Mcl-1, and survivin), proliferation (cyclin D1), invasion (MMP-9, CXCR4, Rho, and Rac), and angiogenesis (VEGF) (23,25,28,33). Findings of the present study showed that MIN also downregulated STAT3-mediated protein expression such as cyclin D1, Bcl-2, Bcl-xL, CXCR4, and VEGF. In a previous study, the inhibitory effect of MIN on CXCR4 expression was found to be mediated via the blockade of transcription factor NF-κB (15). A gene that contains only NF-κB binding sites may be responsive to NF-κB, but not STAT3. However, a gene that contains both NF-κB and STAT3 binding sites may be regulated by both in a cooperative manner (34). Thus, investigation of the key role of MIN on crosstalk between STAT3 and NF-κB is imperative.

Since MIN inhibited the expression of proteins related to proliferation (cyclin D1), and cell survival (Bcl-2, Bcl-xL), whether MIN affected apoptotic progression was examined. The results showed that MIN upregulated caspase-dependent apoptosis in MDA-MB-231 cells. A major limitation of the present study was that the inhibitory effect of MIN was not examined in other cancer cells or in an animal model.

In conclusion, the results of the present study provide evidence that MIN exerts anticancer activity via inhibition of the JAK/STAT3 signaling pathway, especially in breast cancer cells. Further studies using animal models are required to determine the potential of this molecule as an anticancer drug.

 Acknowledgements

Not applicable.

 Availability of data and materials

All data generated or analyzed during the present study are included in this published article.

 Authors' contributions

BP and BK conceived the study. BK developed the methodology, and obtained and validated the data. BK performed the experiments. BP and KL analyzed and interpreted the data. BK and BP prepared the original draft. BP and KL revised the draft. BK and BP confirm the authenticity of all the raw data. All authors read and approved the final manuscript.

 Ethics approval and consent to participate

Not applicable.

 Patient consent for publication

Not applicable.

 Competing interests

The authors declare that they have no competing interests.

 References DeSantisCSiegelRBandiPJemalABreast cancer statistics, 2011CA Cancer J Clin61409418201110.3322/caac.2013421969133 FoulkesWDSmithIEReis-FilhoJSTriple-negative breast cancerN Engl J Med36319381948201010.1056/NEJMra100138921067385 DeanMFojoTBatesSTumour stem cells and drug resistanceNat Rev Cancer5275284200510.1038/nrc159015803154 BanerjeeKResatHConstitutive activation of STAT3 in breast cancer cells: A reviewInt J Cancer13825702578201610.1002/ijc.2992326559373 LaudisiFCherubiniFMonteleoneGStolfiCSTAT3 interactors as potential therapeutic targets for cancer treatmentInt J Mol Sci191787201810.3390/ijms1906178729914167 GarbersCAparicio-SiegmundSRose-JohnSThe IL-6/gp130/STAT3 signaling axis: Recent advances towards specific inhibitionCurr Opin Immunol347582201510.1016/j.coi.2015.02.00825749511 BeckerCFantiniMCSchrammCLehrHAWirtzSNikolaevABurgJStrandSKiesslichRHuberSTGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signalingImmunity21491501200410.1016/j.immuni.2004.07.02015485627 KunduJChoiBYJeongCHKunduJKChunKSThymoquinone induces apoptosis in human colon cancer HCT116 cells through inactivation of STAT3 by blocking JAK2- and Src-mediated phosphorylation of EGF receptor tyrosine kinaseOncol Rep32821828201410.3892/or.2014.322324890449 WangXCrowePJGoldsteinDYangJLSTAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (Review)Int J Oncol4111811191201210.3892/ijo.2012.156822842992 GuFDubéNKimJWChengAIbarra-Sanchez MdeJTremblayMLBoisclairYRProtein tyrosine phosphatase 1B attenuates growth hormone-mediated JAK2-STAT signalingMol Cell Biol2337533762200310.1128/MCB.23.11.3753-3762.200312748279 LiuCYTsengLMSuJCChangKCChuPYTaiWTShiauCWChenKFNovel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cellsBreast Cancer Res15R63201310.1186/bcr345723938089 WuCSunMLiuLZhouGWThe function of the protein tyrosine phosphatase SHP-1 in cancerGene306112200310.1016/S0378-1119(03)00400-112657462 JooMKParkJJYooHSLeeBJChunHJLeeSWBakYTEpigenetic regulation and anti-tumorigenic effects of SH2-containing protein tyrosine phosphatase 1 (SHP1) in human gastric cancer cellsTumour Biol3746034612201610.1007/s13277-015-4228-y26508024 KwakJHKimHJLeeKHKangSCZeeOPAntioxidative iridoid glycosides and phenolic compounds from Veronica peregrinaArch Pharm Res32207213200910.1007/s12272-009-1137-x19280150 KimBMinYHParkBMinecoside modulates cell invasion via regulation of CXCR4 expression in breast and colon cancer cellsPlanta Med86331337202010.1055/a-1107-327232016931 ParkSShinHParkYChoiIParkBLeeKYCharacterization of inhibitory constituents of NO production from Catalpa ovata using LC-MS coupled with a cell-based assayBioorg Chem805763201810.1016/j.bioorg.2018.05.02329874630 KimBLeeKYParkBCrocin suppresses constitutively active STAT3 through induction of protein tyrosine phosphatase SHP-1J Cell Biochem11832903298201710.1002/jcb.2598028295507 YuHLeeHHerrmannABuettnerRJoveRRevisiting STAT3 signalling in cancer: New and unexpected biological functionsNat Rev Cancer14736746201410.1038/nrc381825342631 MasciocchiDGelainAVillaSMeneghettiFBarloccoDSignal transducer and activator of transcription 3 (STAT3): A promising target for anticancer therapyFuture Med Chem3567597201110.4155/fmc.11.2221526897 KimMMoralesLDJangISChoYYKimDJProtein tyrosine phosphatases as potential regulators of STAT3 signalingInt J Mol Sci192708201810.3390/ijms1909270830208623 HanYAminHMFrankoBFrantzCShiXLaiRLoss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphomaBlood10827962803200610.1182/blood-2006-04-01743416825495 JiaoHBerradaKYangWTabriziMPlataniasLCYiTDirect association with and dephosphorylation of Jak2 kinase by the SH2-domain-containing protein tyrosine phosphatase SHP-1Mol Cell Biol1669856992199610.1128/MCB.16.12.69858943354 RealPJSierraADe JuanASegoviaJCLopez-VegaJMFernandez-LunaJLResistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cellsOncogene2176117618200210.1038/sj.onc.120600412400004 WangJXuJXingGLycorine inhibits the growth and metastasis of breast cancer through the blockage of STAT3 signaling pathwayActa Biochim Biophys Sin (Shanghai)49771779201710.1093/abbs/gmx07628910973 LiuXXiaoQBaiXYuZSunMZhaoHMiXWangEYaoWJinFActivation of STAT3 is involved in malignancy mediated by CXCL12-CXCR4 signaling in human breast cancerOncol Rep3227602768201410.3892/or.2014.353625310198 NiuGWrightKLHuangMSongLHauraETurksonJZhangSWangTSinibaldiDCoppolaDConstitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesisOncogene2120002008200210.1038/sj.onc.120526011960372 JohnstonPAGrandisJRSTAT3 signaling: Anticancer strategies and challengesMol Interv111826201110.1124/mi.11.1.421441118 BurkeWMJinXLinHJHuangMLiuRReynoldsRKLinJInhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cellsOncogene2079257934200110.1038/sj.onc.120499011753675 WangTNiuGKortylewskiMBurdelyaLShainKZhangSBhattacharyaRGabrilovichDHellerRCoppolaDRegulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cellsNat Med104854200410.1038/nm97614702634 IhleJNSTATs: Signal transducers and activators of transcriptionCell84331334199610.1016/S0092-8674(00)81277-58608586 SchreinerSJSchiavoneAPSmithgallTEActivation of STAT3 by the Src family kinase Hck requires a functional SH3 domainJ Biol Chem2774568045687200210.1074/jbc.M20425520012244095 HuangTTSuJCLiuCYShiauCWChenKFAlteration of SHP-1/p-STAT3 signaling: A potential target for anticancer therapyInt J Mol Sci181234201710.3390/ijms1806123428594363 SantoniMMassariFDel ReMCiccareseCPivaFPrincipatoGMontironiRSantiniDDanesiRTortoraGCascinuSInvestigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancerExpert Opin Investig Drugs24809824201510.1517/13543784.2015.102037025746129 GrivennikovSIKarinMDangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancerCytokine Growth Factor Rev211119201010.1016/j.cytogfr.2009.11.00520018552

MIN downregulates constitutive activation of STAT3 in MDA-MB-231 cells. (A) Chemical structure of minecoside (MIN) (B) MDA-MB-231 cells (1×104 cells/ml) were treated with the indicated concentrations of MIN. The cell viability was assessed by CCK-8 assays and the results are expressed as percentage of surviving cells over control cells. (C) MIN inhibits STAT3 phosphorylation in a dose-dependent manner. MDA-MB-231 cells were treated with the indicated concentrations of MIN for 24 h. Subsequently, western blotting was performed as described in Materials and methods. (D) MIN inhibits STAT3 phosphorylation in a time-dependent manner. Western blotting was performed after MDA-MB-231 cells were treated with 50 µM MIN for the indicated times (0, 6, 12 and 24 h). (E) MIN suppresses p-JAK1, p-JAK2 and p-Src expression in a dose-dependent manner. After MDA-MB-231 cells were treated with the indicated concentrations of MIN for 24 h, the protein expression of p-JAK1, p-JAK2 and p-Src was observed by western blot analysis. Data indicate mean ± SEM of three independent experiments. *P<0.05, **P<0.01, ***P<0.001 vs. control.

MIN suppresses DNA binding of STAT3 in MDA-MB-231 cells. (A) MIN suppresses STAT3-DNA binding activity in a dose-dependent manner. MDA-MB-231 cells were treated with the indicated concentrations of MIN for 24 h and STAT3-DNA binding activity was measured by EMSA. (B) MDA-MB-231 cells were treated with 50 µM MIN for the indicated times and analyzed for nuclear STAT3 levels by EMSA. (C) MIN inhibits nuclear translocation of STAT3 in MDA-MB-231 cells. After treatment with MDA-MB-231 cells with 50 µM MIN for 24 h, nuclear translocation of STAT3 was measured by immunofluorescence. Scale bars: 100 µm (magnification, ×200). The third panels show the merged images of the first and second panels. The fold of STAT3 positive cells with fluorescence was quantified using ImageJ. ***P<0.001 vs. control.

MIN inhibits the expression of various genes involved in growth, angiogenesis, invasion, and metastasis. (A) MIN induces the expression of SHP-1 protein in MDA-MB-231 cells. After MDA-MB-231 cells were treated with indicated concentrations of MIN for 24 h, whole cell extracts were prepared and the protein expression of SHP-1 was observed by western blot analysis. (B and C) MIN suppresses various gene products involved in survival, apoptosis, and invasion.

MIN induces caspase-dependent apoptosis in MDA-MB-231 cells. (A and B) MIN induces cleavage of caspase-9, −3, and PARP. Whole cell extracts were subjected to western blotting against a cleaved form of caspase-9, caspase-3 and PARP. (C) MDA-MB-231 cells were treated with 50 µM MIN for 24 h, fixed with 4% paraformaldehyde, permeabilized with 0.2% Triton X-100, and stained with labeled TUNEL reagent. The third panels show the merged images of the first and second panels. Scale bars: 100 µm (magnification, ×200).